Integrated
Annual Report 2019

View our purpose, ambition and goal

Our purpose

We create value for patients now and into the future.

We want to give people with severe diseases the freedom to live their best lives. We work in a way that is sustainable for the patients who need our solutions, for the communities where we operate and for society.

Read more

Our strategic approach starts with the deepest knowledge of the patients to deliver sustainable value for patients, our employees, society and shareholders.

Jean-Christophe Tellier, Chief Executive Officer
Read the letter to our stakeholders

Our ambition for patients

Our ambition relies on our ability to innovate to bring differentiated solutions and unique outcomes that help specific patients achieve their life goals and create the best individual experience for them. This also means ensuring access for all who need these solutions, in a way which is viable for patients, society and UCB.
We believe that to fulfill our ambition for patients we must create the right conditions for our employees, the communities in which we operate and our shareholders. We cannot do that alone and we embrace partnerships with other healthcare system stakeholders.

Read more

In our words

  • Emmanuel Caeymaex

    At UCB we aim to create unique value for specific patient populations. We are proud of the difference we are making for patients that didn’t have a solution before, like those suffering from a debilitating inflammatory back condition called non-radiographic axial spondyloarthritis.

    Emmanuel Caeymaex, Executive Vice President, Immunology Solutions & Head of U.S.
    Read more & watch video statement
  • Dhaval Patel

    A differentiated solution means providing treatments to address real patient needs, where it matters most to them.

    Dhaval Patel, Executive Vice President & Chief Scientific Officer
    Read more & watch video statement
  • Iris Löw-Friedrich

    A unique outcome is an outcome that is clearly recognized as impacting the health and life of people with severe diseases in the eyes of all stakeholders, not only patients, but also payers and physicians.

    Iris Löw-Friedrich, Executive Vice President & Chief Medical Officer
    Read more & watch video statement
  • Charl van Zyl

    We are committed to developing solutions that address areas of acute need while delivering sustainable value for people living with myasthenia gravis and other serious, rare, immune-related neurological diseases.

    Charl van Zyl, Executive Vice President, Neurology Solutions & Head of EU/International.
    Read more & watch video statement
  • Kirsten Lund-Jurgensen

    Our colleagues at UCB are very innovative. They have the space to do the best possible job to deliver a medicine to the patient that meets their needs. Innovation starts at the beginning of development and continues through to bringing the solution to patients.

    Kirsten Lund-Jurgensen, Executive Vice President, Supply & Technology Solutions
    Read more & watch video statement
  • Jean-Luc Fleurial

    We need to ask ourselves how we can bring more value to patients.

    Jean-Luc Fleurial, Executive Vice President & Chief Human Resources Officer
    Read more & watch video statement

Our goal

In 2025, we aim to be a leader in specific patient populations.

Read more

Key figures

  • Revenue

    in € million

    4 913

    2018: 4 632

  • rEBITDA/revenue
    ratio

    29.1%

    2018: 30.2%

  • Number of assets in pipeline

    7

    2018: 10

  • R&D/revenue
    ratio

    26%

    2018: 25%

  • 7 606

    UCB employees world-wide

  • 50

    %

    Women

    50

    %

    Men

  • 33

    %

    Women Executive level

    38

    %

    Women Board Member

  • Reduction in CO2 emissions

    −35%

    2018: −30%

  • UCB focuses on the following UN Sustainable Development Goals:

See Our performance

Further insights

  • Key figures
    comparison

    Compare our results with previous years.

    View interactive charts Key figures comparison
  • GRI
    standards

    This Report is prepared in accordance with the core criteria of the Global Reporting Initiative (GRI).

    View GRI standards GRI standards
  • Downloads
    overview

    All report downloads in one place: PDF chapters and XLS tables.

    View Downloads Downloads

About this report

This Integrated Annual Report 2019 includes the management report in accordance with article 12 of the Royal Decree of 14 November 2007 relating to the obligations of issuers of financial instruments admitted to trading on a regulated market. All information required to be included in such management report pursuant to articles 3:6 and 3:32 of the Belgian Code of Companies and Associations (i.e. Corporate Governance Statement – Remuneration Report included –, Business Performance Review and UCB’s Statement on non-financial information) is reported throughout all different sections of this Integrated Annual Report. This 2019 Integrated Annual Report together with the materiality assessment have been prepared in accordance with the Global Reporting Standards: Core option. Non-financial information is also audited by a third party.